Table 2.
Correlation between miR-196a expression and clinicopathological characteristics of 72 HCC Patients
| Clinicopathological feature | miR-196a expression | P value | |
|---|---|---|---|
| High n (%) | Down n (%) | ||
| Age | >0.05 | ||
| <55 years | 23 (57.5) | 17 (42.5) | |
| ≥55 years | 17 (53.1) | 15 (46.9) | |
| Gender | >0.05 | ||
| Female | 17 (60.7) | 11 (39.3) | |
| Male | 23 (52.3) | 21 (47.7) | |
| Tumor size | <0.05 | ||
| >5 cm | 30 (61.2) | 19 (38.8) | |
| ≤5 cm | 10 (43.5) | 13 (56.5) | |
| AFP (μg/L) | >0.05 | ||
| Normal | 19 (55.9) | 15 (44.1) | |
| Abnormal | 21 (55.3) | 17 (44.7) | |
| HBsAg | >0.05 | ||
| Present | 27 (51.9) | 25 (48.1) | |
| Absent | 13 (65) | 7 (35) | |
| Lymph node metastasis | <0.05 | ||
| Yes | 12 (60) | 8 (40) | |
| No | 28 (53.8) | 24 (46.2) | |
| TNM stage | <0.05 | ||
| I–II | 12 (42.9) | 16 (57.1) | |
| III–IV | 28 (63.6) | 16 (36.4) | |
| ALBI grade | <0.05 | ||
| 1 | 13 (46.4) | 15 (53.6) | |
| 2 | 25 (59.5) | 17 (40.5) | |
| 3 | 2 (100) | 0 (0) | |
AFP: alpha-fetoprotein; HBsAg: hepatitis B surface antigen;
TNM: tumor-node-metastasis; ALBI: albumin–bilirubin.